Price movement over the last 24 hours
ADMA Biologics Inc vs United States Copper Index Fund — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while United States Copper Index Fund trades at $37.06. The key difference: United States Copper Index Fund is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | CPER | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $20.38 | $40.60 |
52-Week Low | $7.60 | $27.21 |
Enterprise Value | $2.20B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
CPER, the United States Copper Index Fund ETF, trades at $37.84, up 1.47% today. The technical outlook is mixed, with a bullish moving average signal but neutral overall momentum. Recent news highlights strong copper demand from AI and electric vehicles, though supply constraints and price volatility are key themes. Financial ratios are not applicable as this is a commodity ETF tracking copper futures.
The outlook for CPER is tied to copper's structural bull market, driven by AI and green energy demand. Risks include global manufacturing weakness and commodity price swings. Investor sentiment is positive due to copper's supply-demand imbalance, but the ETF's performance remains sensitive to macroeconomic factors.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →